Equillium Inc

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three abstracts were accepted for presentation at ACR Convergence, the annual meeting of the American College of Rheumatology. The meeting, the world's premier virtual rheumatology experience, will take place online November 3 - 10. Title: Itolizumab, a Novel anti-CD6

Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference, taking place September 27 – 30, 2021. Bruce Steel, Equillium's chief executive officer, and Dolca Thomas M.D., Equillium's executive vice president of re

Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place September 13 – 15, 2021. The virtual on-demand presentation will be available as of Monday, September 13, 2021, at 7:00 am ET. Bruce Steel, Equillium's chief executive office

Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Equillium Inc (NASDAQ: EQ) announced additional data from the Type A portion of the EQUALISE Phase 1b study of itolizumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN). The new data showed that patients without a diagnosis of LN but with elevated urine protein/creatine ratio (UPCR) experienced a mean decrease from baseline in UPCR of 33% and 42% at Days 29 and 57, respectively.

Equillium's Itolizumab Reduces Urine Protein In Lupus Patients

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #lupus--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced additional data from the EQUALISE Type A portion of the study in systemic lupus erythematosus (SLE) patients. The exploratory data set shows that patients without a diagnosis of lupus nephritis (LN) but with elevated urine protein/creatine ratio (UPCR) >200 mg/g (N=6, b

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2021, and provided an update on its clinical programs. “The second quarter of the year was highlighted by positive data from our Phase 1b EQUATE study in acute graft-versus-host disease,” said Bruce Steel, chief executive officer at

Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #asthma--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the BTIG Virtual Biotechnology Conference, taking place August 9 & 10, 2021. Bruce Steel, Equillium's chief executive officer, and Dolca Thomas, M.D., Equillium's executive vice president of research and development and chief medical officer, will provide a high-level overv

Equillium to Present at the BTIG Virtual Biotechnology Conference

Equillium Inc (NASDAQ: EQ) completed an End-of-Phase 1 meeting with the FDA, confirming to advance itolizumab into a single Phase 3 pivotal study in first-line treatment of acute graft-versus-host disease (aGVHD) patients. The company plans to initiate the Phase 3 study in 4Q of 2021.

Equillium's Single Phase 3 Study In aGVHD To Support US Filing Of Itolizumab

The stock price of Equillium Inc (NASDAQ: EQ) increased by over 7% pre-market. This is why it happened.

EQ Stock Increases Over 7% Pre-Market: Why It Happened

Single pivotal Phase 3 study in acute graft-versus-host disease to support filing of biologics license application

Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Checkpoint Therapeutics

Flexion Therapeutics

ReShape Lifesciences

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential

Equillium Inc (NASDAQ: EQ) has announced positive topline data from the Phase 1b EQUATE study evaluating itolizumab in first-line acute graft-versus-host-disease (aGVHD). The results were presented at the European Hematology Association 2021 Virtual Congress.

Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients

Itolizumab continues to demonstrate favorable safety and efficacy profile

Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseases Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseases

Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021.

Equillium to Present at the JMP Securities Life Sciences Conference

LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a translational research collaboration with the Kennedy Institute for Rheumatology and the Sir William Dunn School of Pathology, University of Oxford. The research collaboration will study how CD6 monoclonal antibodies, such as itolizumab, modulate T cell responses and explore the role of the CD6-ALCAM pathway in rheumatic diseases. CD6 is a co-stimulatory receptor, predominantly expressed on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presenting cells and various epithelial and endothelial tissues. The CD6-ALCAM pathway plays an integral role in modulating T cell activation, proliferation, differentiation and trafficking and is believed to play a central role in many autoimmune disorders.

Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases

Presentation and conference call will include topline data from all cohorts

Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11

Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus

Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update

LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that an abstract highlighting positive data from the EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted for oral presentation at EHA2021 Virtual Congress. The annual meeting of the European Hematology Association will be held virtually June 9 – 17, 2021.

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients

Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists

The stock price of Equillium, Inc. (Nasdaq: EQ) has increased by over 5% pre-market. This is why it happened.

EQ Stock Price Increased Over 5% Pre-Market: Why It Happened

Equillium Inc (NASDAQ: EQ) has reported topline data from the Type A group of the Phase 1b EQUALISE study evaluating itolizumab in patients with systemic lupus erythematosus (SLE). Data from the study showed that itolizumab was safe and well-tolerated and demonstrated a dose-dependent reduction of cell-surface CD6 expression on effector T cells, a leading indicator of drug activity.

Equillium's Itolizumab Shows Encouraging Safety, Tolerability Profile In Systemic Lupus Erythematosus Study

Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus

Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients

Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update

EQUATE acute graft-versus host disease (aGVHD) study observed  rapid response and durability through day 85

Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation

News for Equillium Inc Stock (EQ)